

Continuation of Substance of Interview including description of the general nature of what was discussed: Discussed the allowance of the subject matter of claim 1 due to the evidence of synergism of the Rho kinase inhibitor (R)- (+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide with the β -blocker is timolol in the reduction of the intraocular pressure. Discussed the rejoinder of claim 5 with amendments to be commensurate in scope with allowable claim 1, with cancellation of the remaining claims. Received call from Applicant agreeing to the amendments on November 23, 2010.